Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University | UNKNOWN |
| Regional Children's Clinical Hospital, Yekaterinburg | UNKNOWN |
| Morozov Children's Municipal Clinical Hospital of the Moscow City Health Department State-Financed H |
Not provided
Not provided
Not provided
Nijmegen breakage syndrome is one of the DNA repair defect disorders. A characteristic feature of these syndromes is a predisposition to the development of malignant neoplasms. The only curative option for the combined immunodeficiency in Nijmegen breakage syndrome is allogeneic hematopoietic stem cell transplantation (HSCT). In addition to correcting the immunodeficiency, HSCT can reduce the risk of developing hematopoietic tumors.
Due to the increased sensitivity of cells in patients with Nijmegen breakage syndrome to alkylating drugs, the use of standard myeloablative conditioning regimens for this disease significantly increases the risks of toxic complications and transplant-related mortality.
Treosulfan is an alkylating agent that has demonstrated efficacy with comparatively low risks of toxic complications when used as part of conditioning prior to allogeneic HSCT for various diseases in patients of all age groups. There is currently experience using treosulfan in patients with Nijmegen breakage syndrome at reduced doses (21 and 30 g/m²). However, a number of questions remain unresolved. Based on our previous experience, a dose of 21 g/m² is sufficient for patients with Nijmegen breakage syndrome without a malignant disease, as it ensures good graft function (a high probability of full donor chimerism and control of the immunodeficiency). At the same time, there is reason to believe that this dose is insufficient to provide an antitumor effect from the conditioning.
We are planning a multicenter study to investigate treosulfan-based conditioning in patients with Nijmegen breakage syndrome, which will stratify patients based on the presence or absence of malignant disease. Patients without a tumor will receive treosulfan at a dose of 21 g/m², and patients with a tumor will receive 30 g/m².
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with Nijmegen breakage syndrome without malignant disease. | Active Comparator |
| |
| Patients with Nijmegen breakage syndrome and malignant disease. | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treosulfan (Treo) | Drug | We are planning a multicenter study to investigate treosulfan-based conditioning in patients with Nijmegen breakage syndrome, which will stratify patients based on the presence or absence of malignant disease. Patients without a tumor will receive treosulfan at a dose of 21 g/m², and patients with a tumor will receive 30 g/m² |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate event-free survival (EFS), defined by the occurrence of death, graft rejection, or development of secondary malignancy/relapse. | Event-free survival in patients with Nijmegen syndrome is the primary criterion for assessing the effectiveness of HSCT. It was precisely the need to solve the problems of graft rejection, relapses of malignant diseases, and secondary tumors that became the main reasons for initiating this study. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | 2 years | |
| To evaluate the rate of transplant-associated mortality. | 2 years | |
| Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dmitry Balashov, MD, PhD | Contact | +7-926-579-78-17 | bala8@yandex.ru | |
| Alexandra Laberko, MD, PhD | Contact | +7-903-299-49-58 | alexandra-lab@yandex.ru |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D049932 | Nijmegen Breakage Syndrome |
| ID | Term |
|---|---|
| D049914 | DNA Repair-Deficiency Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C018404 | treosulfan |
Not provided
Not provided
Not provided
| OTHER_GOV |
| Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation | UNKNOWN |
We are planning a study to investigate treosulfan-based conditioning in patients with Nijmegen breakage syndrome, which will stratify patients based on the presence or absence of malignant disease. Patients without a tumor will receive treosulfan at a dose of 21 g/m², and patients with a tumor will receive 30 g/m².
Not provided
Not provided
Not provided
Not provided
|
| 3 months |
| Probability of graft rejection | 2 years |
| Frequency of Complete Donor and Mixed Chimerism after HSCT | 1 year |
| Incidence of acute GVHD. | 1 year |
| Incidence of chronic GVHD. | 2 years |
| To assess the kinetics of immune reconstitution | 1 year |